Abstract
With a lifetime prevalence of more than 16% worldwide, major depressive disorder is one of the most common psychiatric disorders. Only one third of patients experience a complete therapeutic improvement with the use of current antidepressant drugs, with a therapeutic effect appearing only after several weeks of treatment. Hence, a better understanding of the mechanisms of action of current antidepressant treatments is needed to ultimately identify new targets and enhance beneficial effects. Given the intimate relationships between astrocytes and neurons at synapses and the ability of astrocytes to “sense” neuronal communication and release gliotransmitters, an attractive hypothesis is emerging stating that the effects of antidepressants on brain function could be, at least in part, mediated by direct influences of astrocytes on neuronal networks. This review aims at highlighting the involvement of astrocytes and gliotransmission in the antidepressant effects of both non- and pharmacological therapies.
Keywords: Antidepressants, astrocytes, DBS, gliotransmission, tripartite synapse.
Current Drug Targets
Title:Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Volume: 14 Issue: 11
Author(s): Adeline Etiévant, Laura Lambás-Señas, Hélène Scarna, Guillaume Lucas and Nasser Haddjeri
Affiliation:
Keywords: Antidepressants, astrocytes, DBS, gliotransmission, tripartite synapse.
Abstract: With a lifetime prevalence of more than 16% worldwide, major depressive disorder is one of the most common psychiatric disorders. Only one third of patients experience a complete therapeutic improvement with the use of current antidepressant drugs, with a therapeutic effect appearing only after several weeks of treatment. Hence, a better understanding of the mechanisms of action of current antidepressant treatments is needed to ultimately identify new targets and enhance beneficial effects. Given the intimate relationships between astrocytes and neurons at synapses and the ability of astrocytes to “sense” neuronal communication and release gliotransmitters, an attractive hypothesis is emerging stating that the effects of antidepressants on brain function could be, at least in part, mediated by direct influences of astrocytes on neuronal networks. This review aims at highlighting the involvement of astrocytes and gliotransmission in the antidepressant effects of both non- and pharmacological therapies.
Export Options
About this article
Cite this article as:
Etiévant Adeline, Lambás-Señas Laura, Scarna Hélène, Lucas Guillaume and Haddjeri Nasser, Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990197
DOI https://dx.doi.org/10.2174/13894501113149990197 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Extracellular Level of GABA and Glu: In Vivo Microdialysis-HPLC Measurements
Current Topics in Medicinal Chemistry Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands
Current Neuropharmacology Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
Current Pharmaceutical Design Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s Disease: Retrospective Medical Record Review Study and a Nested Case-control Design
Current Alzheimer Research Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Drug Development Against Sleeping Sickness: Old Wine in New Bottles?
Current Medicinal Chemistry Current State of Development of Genome Analysis in Livestock
Current Genomics A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Toxic Metals in Herbal Medicines. A Review
Current Bioactive Compounds